INVO Bioscience Inc INVO

NAS: INVO | ISIN: US44984F3029   20/05/2024
0,929 USD (-5,69%)
(-5,69%)   20/05/2024

9 november 2023 · INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants · Persbericht

31 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, INVO, NM · Persbericht

27 oktober 2023 · Free Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023 · Persbericht

25 oktober 2023 · Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma? · Persbericht

24 oktober 2023 · Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma? · Persbericht

23 oktober 2023 · Shareholder Alert: Ademi LLP investigates whether INVO Bioscience, Inc. has obtained a Fair Price in its transaction with NAYA Biosciences · Persbericht

23 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ESMT, NM, INVO · Persbericht

11 oktober 2023 · INVO to Participate in the Lytham Partners Fall 2023 Investor Conference · Persbericht

29 september 2023 · Invo Bioscience Announces Adjournment Of Special Meeting Of Shareholders · Persbericht

4 augustus 2023 · INVO Bioscience Announces Pricing of $4.5 Million Public Offering · Persbericht

27 maart 2023 · INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering · Persbericht

5 januari 2023 · INVO Bioscience Enters Distribution Agreement for Taiwan · Persbericht

14 november 2022 · INVO Bioscience Reports Third Quarter 2022 Financial Results · Persbericht

1 november 2022 · INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo · Persbericht

21 oktober 2022 · INVOcell Review Published in Current Opinion in Obstetrics and Gynecology · Persbericht

25 augustus 2022 · INVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz · Persbericht

4 augustus 2022 · INVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022 · Persbericht

Mijn selecties